Drug Trial Radar · NCT06999551
Comparison of the Efficacy and Safety of GLARGEN® Versus NPH Insulin in Diabetic Tunisian Patients.
Last checked: Nov 20, 2026Latest source record: May 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jul 1, 2025
Primary completion
Dec 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Les Laboratoires des Médicaments StérilesIndustry
- Sponsor type
- Industry
- First posted
- May 31, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will have a single arm: the patient on NPH will continue his treatment for 4 weeks, at the end of the NPH treatment, the patient will receive his CGM device for three days for glycemic holter, a switch to insulin glargine is started for a period of 12 weeks with a dose adjustment and a control of the glycemic balance by CGM for three days at the end of the study. The NPH insulin vial is a 10 ml vial dosed at 100 IU/mL, The Glargen vial is in the form of a solution for injection, a 3 ml vial dosed at 100 IU/mL
Conditions
- Diabetes Mellitus
Interventions
switch NPH to glarginDrug
Switch of patients with type 2 diabetes mellitus from NPH insulin to insulin glargine
Primary outcomes
What the sponsor says the trial is designed to measure.
- glycaemic variability on insulin glargine (after 12 weeks of use) versus NPH insulin (baseline)Time frame: 4 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hedi Chaker Hospital
Sfax, Tunisia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.